Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 31, 2007 Brian Lawler	Bad Alkermes? The drug-delivery expert releases financial results and includes a little negative surprise for investors.
The Motley Fool February 11, 2009 Brian Orelli	The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder.
The Motley Fool September 23, 2009 Robert Steyer	Alkermes Needs Some Financial Alchemy After a string of research and marketing disappointments, the company's CEO departs.
The Motley Fool March 20, 2008 Brian Lawler	The AIR's Knocked Out of Alkermes Drug developer Alkermes initiates a round of cost-cutting.
The Motley Fool May 19, 2009 Brian Orelli	Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies.
The Motley Fool October 13, 2010 Brian Orelli	Don't Get Addicted to Alkermes' Low Revenue Vivitrol's launch and the approval of Bydureon will drive revenue -- and Alkmeres' stock price -- in the future.
The Motley Fool February 7, 2005 Brian Gorman	Alkermes Is Coming of Age The drug delivery company may soon have its own drug on the market.
The Motley Fool August 27, 2008 Brian Orelli	Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note.
The Motley Fool August 27, 2009 Brian Orelli	Elan and J&J, Sitting in a Tree ... Johnson & Johnson dumps Alkermes for its new best bud in favor of Elan
The Motley Fool July 6, 2007 Brian Lawler	Another Round for Alkermes' Alcohol Fight Alkermes advances the development of another drug. Investors, take note.
The Motley Fool June 11, 2007 Brian Lawler	More Air for Alkermes The biopharmaceutical drug delivery expert brings another drug into clinic stage testing. Investors, take note.
The Motley Fool May 9, 2011 Brian Orelli	In Biotech, Two Platforms Are Better Than One Alkermes has swooped in and agreed to buy Elan Drug Technology for around $960 million.
The Motley Fool April 8, 2005 Stephen D. Simpson	Alkermes' Alcohol Alchemy A new formulation of an old drug could help alcoholics and make shareholders happy.
The Motley Fool August 24, 2007 Brian Orelli	Kids, Take Your Psychoactives J&J gains pediatric approval of its antipsychotic drug. Investors, take note.
The Motley Fool February 10, 2009 Brian Orelli	Roses and Candy From the FDA? Some drugmakers expect the FDA to bestow its kiss of approval this month. Read on to see who.
The Motley Fool April 21, 2010 Brian Orelli	Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant.
The Motley Fool March 21, 2007 Brian Lawler	Acadia Ascending Shares of Acadia Pharmaceuticals soared by more than 100% following successful results from a phase 2 trial for schizophrenia drug candidate ACP-103.
The Motley Fool October 30, 2007 Brian Lawler	Lasting Longer Courtesy of Elan Elan announces that partner Johnson & Johnson has filed a marketing application for a once-a-month form of its anti-psychotic drug Invega. Investors, take note.
The Motley Fool April 15, 2011 Luke Timmerman	Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe?
The Motley Fool April 15, 2011 Brian Orelli	Fewer Needle Pricks for the Europeans Amylin's once-weekly diabetes drug Bydureon gets a positive recommendation in Europe.
The Motley Fool June 27, 2005 Brian Gorman	Alkermes' Powerful Partnership Alkermes recently agreed to partner with Cephalon to commercialize Alkermes' Vivitrex, an experimental drug to treat alcoholism. The deal should bring strong sales and valuable experience.
The Motley Fool March 15, 2010 Brian Orelli	FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
The Motley Fool December 14, 2009 Brian Orelli	Finally Released From an Extended Review The FDA finally approves extended-release Zyprexa.
Chemistry World March 26, 2014 Phillip Broadwith	$1.2bn J&J deceptive marketing fine overturned The Arkansas Supreme Court has overturned a lower court's fine of $1.2 billion, imposed on Johnson & Johnson's subsidiary Janssen in April 2012 over its marketing of antipsychotic drug Risperdal (risperidone).
The Motley Fool October 13, 2009 Brian Orelli	J&J Needs to Get Drugged Up Medical devices and diagnostics pass by drugs as the main revenue source.
The Motley Fool June 18, 2010 Brian Orelli	Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed.
The Motley Fool January 8, 2009 Brian Orelli	FDA Toys With Lilly, and Investors, Again Eli Lilly will have to wait a little longer.
BusinessWeek March 11, 2010 Margaret Cronin Fisk et al.	Did J&J Plan to Break Rules? Its aggressive marketing campaign for Risperdal has caused an explosion of litigation.
The Motley Fool February 29, 2008 Brian Lawler	FDA Floors Eli Lilly Eli Lilly receives an especially harsh rebuke from the FDA about one of its top candidates when the agency refused to approve a long-lasting injection version of its multibillion-dollar Zyprexa for schizophrenia and bipolar disorder.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
The Motley Fool October 28, 2011 Brian Orelli	Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
The Motley Fool October 8, 2008 Brian Orelli	Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states.
The Motley Fool June 27, 2006 Brian Lawler	Cephalon Stays Busy The announcement of Gabitril's phase 3 failure was definitely not good news for Cephalon. However, if the market panics and drives the stock down, investors could find themselves with a great buying opportunity.
The Motley Fool October 22, 2007 Brian Lawler	Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future.
The Motley Fool September 15, 2008 Brian Orelli	Teva and FDA's Never-Ending Court Battle The Food and Drug Administration has won the latest installment of its grudge match with Teva Pharmaceuticals over the 180-day exclusivity period for generic versions of Johnson & Johnson's Risperdal.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
The Motley Fool July 8, 2011 Luke Timmerman	Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial What does this mean for the drug companies?
The Motley Fool November 24, 2009 Brian Orelli	4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc.
The Motley Fool July 14, 2009 Brian Orelli	J&J Eats a Hard Quarter Tough year-over-year comparisons are no match for the health care giant.
The Motley Fool January 2, 2012 Anders Bylund	What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012.
The Motley Fool November 9, 2006 Shruti Basavaraj	The Best Blue Chip for 2007: Johnson & Johnson If you're out looking for the best blue chip money can buy, consider Johnson & Johnson. The stock combines strong growth opportunities with stability. It's the ideal stock to build the core of your portfolio.
Chemistry World November 11, 2013 Sarah Houlton	Mis-selling lands J&J with $2.2bn fine Johnson & Johnson has been given a hefty fine in the US for mis-selling three drugs. The company, and its subsidiaries Janssen and Scios, will pay $2.2 billion.
The Motley Fool March 5, 2008 Brian Orelli	Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent.
The Motley Fool February 16, 2007 Brian Lawler	Cephalon's Supercharged Growth The pharmaceutical announces fourth-quarter results and updates 2007 guidance. Investors, take note.
The Motley Fool September 11, 2008 Brian Orelli	Vive le Vioxx Lawsuit Just when Merck thought it was finally done with lawsuits pertaining to Vioxx, it's gotten pulled back in.
The Motley Fool October 18, 2005 Nathan Slaughter	Good Teamwork at J&J The health-care giant tops third-quarter estimates on strong sales of medical devices.